Tag: Hancock Jaffe

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has entered into a Sponsored Research Agreement with Texas Heart Institute for the development of HJLI’s CoreoGraft®, an off […]

Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City

IRVINE, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, today announced that it will present and meet with potential investors at The MicroCap Conference on October 1 and 2 at The Essex […]

Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia

IRVINE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has completed and submitted its application to INVIMA (the Colombian equivalent of the US FDA) for approval of its […]

New Study Confirms Significant Potential U.S. Market for Hancock Jaffe’s VenoValve®

IRVINE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, has commissioned a research report from The Sage Group, a research organization specializing in peripheral vascular disease. The report, titled “Chronic Venous Disease: Epidemiology […]

Hancock Jaffe Laboratories Receives Medical Research Committee Approval for First-in-Human VenoValve Study

IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in bioprosthetic medical devices that establish improved standards of care for treating cardiac and vascular diseases, today announced that it has received approval for the first-in-human testing of its VenoValve® bioprosthetic medical […]

Hancock Jaffe Laboratories Receives Ethics Committee Approval for First-in-Human VenoValve Study

IRVINE, Calif., July 24, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has received approval from the Ethics Committee at Fundación Santa Fe de Bogotá […]

Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer

IRVINE, Calif., July 13, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that Bob Rankin will be joining the company as its chief financial officer beginning July […]

Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve

IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has initiated an analysis of its bioprosthetic heart valve in order to determine […]

Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study

IRVINE, Calif., June 20, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has selected Fundación Santa Fe de Bogotá (“FSFB”), in Bogota Columbia, as the […]